Oral semaglutide and cardiovascular outcomes by baseline A1c and BMI in people with type 2 diabetes in the SOUL trial

Silvio E. Inzucchi¹; Rohana Abdul Ghani²; John Deanfield³; Mads D. M. Engelmann⁴; G. Kees Hovingh⁴; Ole K. Jeppesen⁴; Monika Kellerer⁵; Kabirdev Mandavya⁶; Johannes F. Mann⁷; Nikolaus Marx⁸; Chantal Mathieu⁹; Darren K. McGuire¹⁰; Viswanathan Mohan¹¹; Sharon L. Mulvagh¹²; Rodica Pop-Busui¹³; Neil R. Poulter¹⁴; Maria Sejersten Ripa⁴; Gabriela Roman¹⁵; Róbinson Sánchez García¹⁶; Michael Shechter¹⁷; John B. Buse¹⁸; on behalf of the SOUL Study Group